Skip to main content
KYMRKymera Therapeutics, Inc.Sell4.5·$125.85
SellModerate Confidence
Investment thesis

Kymera Therapeutics has strong analyst support and a technical breakout, but the price of $127.57 is within 2.5% of the $130.70 target, quality is 1.8/10 with FCF at -161% of revenue, and downside is 15.0%.

Thesis pillars

  • Leverage Margin Value Trap↓Deteriorating
  • Cash Burning Low Quality→Stable
  • Price Near Analyst Target↑Improving
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Nov 14, 2026, based on the 10-K filed Feb 26, 2026

Full reasoning →

Open full analysis

Kymera Therapeutics, Inc. (KYMR) Stock Analysis

Range Bound setup

SellModerate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $125.85: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 13%; Elevated put/call ratio: 2.61; Below-average business quality.

Kymera Therapeutics is a clinical-stage biopharmaceutical company developing oral targeted protein degraders for immune-inflammatory diseases, with lead programs KT-621 (STAT6, Phase 2b in atopic dermatitis and asthma) and KT-579 (IRF5, Phase 1). Revenue comes from collaboration... Read more

$125.85+3.9% A.UpsideScore 4.5/10#211 of 240 Biotechnology
QualityF-score4 / 9FCF yield-1.53%
Stop $117.04Analyst target $130.70(−10% haircut)A.R:R 0.3:1
Analyst consensus$145.22+15.4%23 analysts with price targets
$130.70Analyst target
$125.85price
$145.22mean
$116
$180

Sell if holding. Engine safety override at $125.85: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 13%; Elevated put/call ratio: 2.61; Below-average business quality. Chart setup: RSI 58 mid-range, Bollinger mid-band. Score 4.5/10, moderate confidence.

Passes 5/8 gates (clean insider activity, news events none recent, earnings proximity 100d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: speculative.

10-K grounded · weekly refresh

About Kymera Therapeutics, Inc.

About Kymera Therapeutics, Inc.

Kymera Therapeutics has advanced its lead STAT6 degrader, KT-621, into two concurrent Phase 2b clinical trials—BROADEN2 in atopic dermatitis and BREADTH in asthma—with data expected by mid-2027 and late-2027, respectively. The company held $1,619.4 million in cash and marketable securities at December 31, 2025, supporting operations through a projected 2029 runway, against an accumulated deficit of $1,066.0 million. KT-579 (IRF5) began Phase 1 testing in healthy volunteers during 2025, and Sanofi plans to advance KT-485/SAR447971 (IRAK4) into clinical testing in 2026.

Kymera generates collaboration revenue rather than product sales. The Sanofi partnership covers IRAK4 degraders outside oncology and immuno-oncology; in June 2025, Sanofi exercised its participation election for KT-485/SAR447971, which it intends to advance clinically in 2026. A separate June 2025 agreement with Gilead Sciences targets CDK2 molecular glue degraders. The company's discovery platform applies targeted protein degradation, a modality that recruits the body's natural ubiquitin-proteasome machinery to eliminate disease-causing proteins—enabling it to target historically undrugged transcription factors such as STAT6 and IRF5. Drug manufacturing is outsourced to contract manufacturers, which the filing identifies as a critical dependency for clinical supply. Net losses were $311.4 million in 2025, $223.9 million in 2024, and $147.0 million in 2023, driven entirely by research, development, and general and administrative costs.

Show full overview

The company's clinical valuation rests heavily on KT-621's Phase 2b data readouts. The 10-K acknowledges that "no product candidate using a heterobifunctional degrader has been approved in the United States or Europe," marking the BROADEN2 and BREADTH trials as binary inflection points for the entire TPD platform thesis. Prior discontinuations—KT-295 (TYK2) in May 2025 and Sanofi's decision to abandon first-generation KT-474 in favor of KT-485 in June 2025—demonstrate that late-stage clinical redirection is possible and can impair program-level investment value.

See also: Healthcare · Biotechnology

From Kymera Therapeutics, Inc.'s most recent 10-K filing, extracted June 11, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

No fresh coverage since Nov 2, 2026

Recent Developments — Kymera Therapeutics, Inc.

Latest item Nov 2, 2026 · Generated 2026-11-17T12:07:51Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Feb 25, 2027100d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Quality below floor (1.8 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)-24.6
Mkt Cap$10.7B
EV/EBITDA-24.7
Profit Mgn0.0%
ROE-27.3%
Rev Growth—
Beta2.03
DividendNone
Analysts with ratings30

Quality Signals

Piotroski F4/9

Options Flow

P/C2.61bearish
IV130%elevated

Concentration Risks(10-K Item 1A)

  • MEDIUMpipelinelead programs
    10-K Item 1A: 'We depend heavily on the successful development of our lead programs.'

Material Events(8-K, last 90d)

  • 2026-06-08Item 5.02MEDIUM
    COO Jeremy Chadwick resigned effective June 5, 2026, citing personal reasons; no disagreement with company practices cited. Chadwick will remain as employee/advisor until November 2026. No successor named.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

3 floor-breakers

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe
0.0
Roa
0.0
Gross Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Piotroski F
4.4
Moat
4.8
Current Ratio
5.0
Cash-burning: FCF -161% of revenueNo competitive moatQuality concerns

Volatile — 6.2% daily ATR makes tight stops impractical. Position-size conservatively.static

Volatility
0.0
Put Call
0.0
Implied Vol
0.0
Days To Cover
0.5
Max Pain Risk
3.0
Beta
3.2
Short Interest
3.7
Debt Equity
9.8
Elevated put/call: 2.61High IV: 130%Above max pain $40

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Obv
1.0
Volume
2.7
Rsi
5.5
Ma Position
9.0
Volume distribution (falling OBV)Above 200-day MA
GatesMomentum 3.6<4.5A.R:R 0.3 < 1.5@spotExecutive change: officer departure/appointmentInsider activity: OKNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 100d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Speculative
RSI
58 · Neutral
↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $108.49Resistance $142.92

Price Targets

$117
$131
A.Upside+3.9%
A.R:R0.3:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! Quality below floor (1.8 < 4.0)
! momentum at 3.6 (below the engine's 4.5 threshold)
! asymmetry at 0.3 (below the engine's 1.5 threshold)@spot

Earnings

B
B
M
M
2/4 beats
Next Earnings2027-02-25 (100d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is KYMR stock a buy right now?

Sell if holding. Engine safety override at $125.85: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 13%; Elevated put/call ratio: 2.61; Below-average business quality. Chart setup: RSI 58 mid-range, Bollinger mid-band. Prior stop was $117.04. Score 4.5/10, moderate confidence.

What is the KYMR stock price target?

Analyst target: $130.70 (+3.9% upside). Prior stop was $117.04. Stop-loss: $117.04.

What are the risks of investing in KYMR?

Quality below floor (1.8 < 4.0).

Is KYMR overvalued or undervalued?

Kymera Therapeutics, Inc. trades at a P/E of N/A (forward -24.6). TrendMatrix value score: 5.0/10. Verdict: Sell.

What do analysts say about KYMR?

30 analysts rate KYMR, with a consensus score of 4.3/5. 23 analysts publish price targets averaging $145.

What does Kymera Therapeutics, Inc. do?Kymera Therapeutics is a clinical-stage biopharmaceutical company developing oral targeted protein degraders for...

Kymera Therapeutics is a clinical-stage biopharmaceutical company developing oral targeted protein degraders for immune-inflammatory diseases, with lead programs KT-621 (STAT6, Phase 2b in atopic dermatitis and asthma) and KT-579 (IRF5, Phase 1). Revenue comes from collaboration agreements with Sanofi and Gilead rather than product sales; the company held $1.6 billion in cash as of December 31, 2025. It has never generated product revenue.

Related stocks: ASND (Ascendis Pharma A/S) · ARGX (argenx SE) · HALO (Halozyme Therapeutics, Inc.) · REGN (Regeneron Pharmaceuticals, Inc.) · BMRN (BioMarin Pharmaceutical Inc.)
Home › Stocks › KYMR

Latest news

Latest News

Fiscal.ai15d agoAnalyst
Benzinga15d agoAnalyst
Benzinga18d agoAnalyst
Benzinga18d agoAnalyst
Fiscal.ai18d agoAnalyst
Fiscal.ai19d ago
Benzinga19d ago
Fiscal.ai20d ago
Benzinga20d ago
Benzinga21d agoAnalyst
Fiscal.ai26d ago
Benzinga39d agoAnalyst
Benzinga39d ago
Benzinga43d agoAnalyst
Benzinga56d agoAnalyst
Benzinga77d agoFda Decision
Benzinga78d ago
Benzinga82d agoAnalyst
Benzinga104d ago
Benzinga110d agoAnalyst
Loading more...